Recently, a couple of interesting items about autism were posted. One was a NYT podcast, and the other was an opinion piece in STAT. Specifically, the unintended consequences of the movement from a categorical diagnostic model (Autistic Disorder and Asperger's Disorder) to a spectrum model (Autism Spectrum Disorder, aka ASD). https://youtu.be/eSwJmsHGrns?si=osfA8RHxkJ38lf2X In the NY Times … Continue reading How important are conceptual boundaries?
Author: Jason Schwartz
I have been an addiction professional and social worker since 1994. I started blogging in 2005 as the Clinical Director at Dawn Farm. I currently serve as the Director of Social Work and Spiritual Care for a healthcare system. I've also served as the Director of Behavioral Health at another hospital. I'm also a lecturer at Eastern Michigan University’s School of Social Work.
Views expressed here are my own.
Keep in mind that the field, the contexts in which the field operates, and my views have changed over time.
Nonabstinence in recovery(?) from what?
Several months ago, The Journal of Addiction Medicine published an article on the prevalence of alcohol and other drug use among adults "in recovery." It drew from the 2022 National Survey on Drug Use and Health and looked at the prevalence of alcohol and other drug use among people who answered yes to the following … Continue reading Nonabstinence in recovery(?) from what?
Recovery Housing Veto in California
California Governor Gavin Newsom recently vetoed a bill that would have allowed local governments to use up to 10% of state homelessness funds for abstinence-based recovery housing. The bill sought to adjust the state's housing-first policies, which prohibit using homelessness funds for abstinence-based recovery housing. A 2016 law adopting the “housing first” model as state policy prohibits … Continue reading Recovery Housing Veto in California
Protection, Remission, and Recovery
Thomas McLellan and Nora Volkow, two very important figures in modern addiction and treatment science, just published a new article. This strikes me as an important and potentially very consequential article. I'll share a few of the things that grabbed my attention. They describe the impetus for this article as follows: Prescribing MOUD with a … Continue reading Protection, Remission, and Recovery
7-OH and the Question of Harm Production
This guest post is by Lee Holley, LCSW, LCDC, PSS. Lee is a psychotherapist based in Texas. He specializes in therapy for people with alcohol and other drug problems through a recovery-oriented harm reduction lens, combining clinical expertise with lived experience in long-term recovery. As a psychotherapist who bases my philosophy of treating alcohol and … Continue reading 7-OH and the Question of Harm Production
Drug Innovation or Contamination?
As harm reduction has risen in prominence and influence in the addiction, treatment, and recovery spaces, one of its contributions to discussions about public policy related to drug use has been the suggestion that prohibition creates a drug supply with unpredictable potency that is vulnerable to contamination, and that these factors drive overdose. This leads … Continue reading Drug Innovation or Contamination?
The AI Mirror: “take that small hit, and you’ll be fine”
I published the post below last month, which resulted in an invitation to speak with DeAnn and Craig Knighton on their podcast, Recovery Discovery. It was a fun conversation and I thought I'd share that with you here. https://open.spotify.com/episode/5YYECT2NeBogNVSehvQm6w?si=auerM5dAQfenEQ6Xn_zN5w I also want to share a couple of things that have come up since the interview. … Continue reading The AI Mirror: “take that small hit, and you’ll be fine”
Private Pain and Public Performance
The Fall of Icarus by Jacob Peeter Gowy I recently read a moving and, sadly, familiar story. It's about a person with addiction who finds recovery and pours himself into advocacy. He seeks an audience and influence, finds an opportunity in harm reduction, distance grows between him and the foundations of his recovery, he relapses, … Continue reading Private Pain and Public Performance
Why won’t the acute care paradigm die?
Recently, I posted about a study finding significant declines in the duration of treatment for MOUD patients in Ontario, Canada. The post focused on the persistence of the acute care paradigm, now appearing in MOUD. The post prompted some discussion on LinkedIn, during which I was struck by how this is really just a cycle … Continue reading Why won’t the acute care paradigm die?
“further research is needed to improve treatment retention”
Kleinman RA, Kurdyak P. Duration of Methadone and Buprenorphine-Naloxone Treatment. JAMA Network Open. 2025;8(7):e2518389. doi:10.1001/jamanetworkopen.2025.18389 An eye-popping article was just published in JAMA about trends in the duration of methadone and buprenorphine treatment in Ontario, Canada, including more than 72,000 new recipients of opioid agonist treatments. The median duration of buprenorphine treatment declined by 25%, … Continue reading “further research is needed to improve treatment retention”
Recovery Review 